fbpx

Cyteir Therapeutics Inc

CYT

$

Closing

1D

YTD

Exchange

Sector

Market cap

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$

Analysts' Rating

HOLD

Price Target (Mean)

3

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth

0.00%

52 week high

$

52 week low

$

Div. Yield

%

EPS Growth

-58.33

Company Profile

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.